Abstract:ABSTRACT Purpose It has been suggested that heavy-ion radiation therapy may contribute to the control of distal metastases. These distant responses may include immune cell activation. Immunostimulation resulting from radiation-induced immunogenic cell death (ICD) of cancer cells, leads to the recruitment of anti-tumor T cells. Specific markers of ICD include translocation of calreticulin (CRT) and extracellular release of high mobility group box 1 protein (HMGB1), and ATP. However, the LET dependence of these effects remains unknown. Materials and Methods Expression of the molecular indicators described above were tested in a panel of human cancer cell lines, that included pancreatic cancer (Panc1 and Paca2), glioblastoma (U87 and LN18) and melanoma (HTB129 and SK-Mel5). Cells were irradiated with 5 Gy of particles spanning a range of LETs, from 10 KeV/μm to 150 KeV/μm and assayed for relocalization of calreticulin and release of HMGB1 and ATP were assayed 24 hours later. Results In the pancreatic cancer cell lines (Panc1 and Paca2) there was a continued increase in the membrane relocalization of calreticulin as a function of increasing LET up to 150 KeV/μm. The melanoma cell lines, HTB129 and Sk-Mel5 showed similar patterns. In contrast, calreticulin levels were higher, but not LET-dependent, in irradiated U87 and LN18 (glioblastoma) lines. With the exception of the response in Paca2, increases in LET correlated with increases in HMGB1 that seemed to peak at 100 KeV/μm and then either remain unchanged or decrease at 150 KeV/μm. while the ATP levels were elevated in media from some of the irradiated groups, there were no clear patterns either by cell type or LET. Conclusions Our results indicate that at equal doses, although there is an overall trend of increases in the responses to increasing LETs, there are significant cell line-specific differences in the patterns of expression of these key ICD markers.

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

Consensus guidelines for the detection of immunogenic cell death.

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments

Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy

Immunogenic Cell Death Induction by Ionizing Radiation

Trial watch: chemotherapy-induced immunogenic cell death in oncology

Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers

Detection of immunogenic cell death and its relevance for cancer therapy

Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

Biomaterials That Induce Immunogenic Cell Death

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities

LET-dependence of radiation-induced makers of Immunogenic Cell Death in human cancer cell lines

Immune targets in the tumor microenvironment treated by radiotherapy

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors

Immunogenic Cell Death in Cancer Therapy

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

The abscopal effect of radiation therapy